Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease

doi:10.4330/wjc.v11.i11.256

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5775)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

269

WORD

217

HTML

3010

Figures (1-1)

288

Tables (1-1)

258

Sum=4042

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

750

Download

983

Sum=1733

Nov 26, 2019 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Cardiol. Nov 26, 2019; 11(11): 256-265
Published online Nov 26, 2019. doi: 10.4330/wjc.v11.i11.256

Full Size Figure Download Figure

Figure 1 Molecular pathways of action and effects of novel lipid-modifying therapies addressing unmet needs in cardiovascular disease. siRNA: Small interfering RNA; ACL: Adenosine triphosphate-citrate lyase; AMPK: Adenosine monophosphate-activated protein kinase; PPARs: Peroxisome proliferator-activated receptors; Apo: Apolipoprotein; ASO: Antisense oligonucleotide; PCSK9: Proprotein convertase subtilisin/kexin type 9; HMG-CoA: 3-hydroxy-3-methylglutaryl-CoA; Lp(a): Lipoprotein (a); LXRs: Liver X receptors; LDL-C: Low-density lipoprotein cholesterol; CEC: Cholesterol efflux capacity.

Citation: Kosmas CE, Sourlas A, Silverio D, Montan PD, Guzman E. Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease. World J Cardiol 2019; 11(11): 256-265
URL: https://www.wjgnet.com/1949-8462/full/v11/i11/256.htm
DOI: https://dx.doi.org/10.4330/wjc.v11.i11.256